Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 17, 2014

SEC-MALS Detector for UHPLC

The ?DAWN can be attached to any UHPLC system to determine molecular weights and sizes of proteins.

Wyatt Technology

introduces the µDAWN, a multi-angle light scattering (MALS) detector that can be attached to any UHPLC system in order to determine molecular weights and sizes of polymers, peptides, and proteins or other biopolymers directly, without resorting to column calibration or reference standards. The µDAWN connects to the Optilab UT-rEX, a refractiveindex detector for UHPLC.

The µDAWN reduces the conventional light scattering flow cell volume from 63 µL to less than 10µL. By minimizing interdetector mixing, the band broadening between the µDAWN MALS and Optilab UT-rEX detectors is under 7 µL, while the band broadening between the UHPLC’s UV detector and the µDAWN detector is 2 µL. As a result of the reduced cell volume and interdetector band broadening, the µDAWN/UT-rEX system can accurately analyze the molar mass and size of UHPLC peaks without loss of resolution.

In addition, the WyattQELS Dynamic Light Scattering (DLS) module measures DLS in the µDAWN flow cell simultaneously with MALS acquisition, quickly computing hydrodynamic radii.

Source:

Wyatt Technology


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.